Reversal of acute allograft rejection with monoclonal antibody

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

OKT3 is a very effective drug when used for reversal of acute allograft rejection. The excellent long-term graft survival of the patients in this study indicates that it is also an effective adjunctive therapy for promoting long-term graft survival. The problems encountered with early rerejection in high responder patients will promote an alteration of currently used protocols to accommodate these patients.

Original languageEnglish (US)
Pages (from-to)39-41
Number of pages3
JournalTransplantation Proceedings
Volume17
Issue number1 I
StatePublished - 1985

Fingerprint

Allografts
Monoclonal Antibodies
Graft Survival
Muromonab-CD3
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Reversal of acute allograft rejection with monoclonal antibody. / Norman, Douglas; Barry, John; Henell, K.

In: Transplantation Proceedings, Vol. 17, No. 1 I, 1985, p. 39-41.

Research output: Contribution to journalArticle

@article{bd0e906b504649f493d4ff0abe8291b4,
title = "Reversal of acute allograft rejection with monoclonal antibody",
abstract = "OKT3 is a very effective drug when used for reversal of acute allograft rejection. The excellent long-term graft survival of the patients in this study indicates that it is also an effective adjunctive therapy for promoting long-term graft survival. The problems encountered with early rerejection in high responder patients will promote an alteration of currently used protocols to accommodate these patients.",
author = "Douglas Norman and John Barry and K. Henell",
year = "1985",
language = "English (US)",
volume = "17",
pages = "39--41",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "1 I",

}

TY - JOUR

T1 - Reversal of acute allograft rejection with monoclonal antibody

AU - Norman, Douglas

AU - Barry, John

AU - Henell, K.

PY - 1985

Y1 - 1985

N2 - OKT3 is a very effective drug when used for reversal of acute allograft rejection. The excellent long-term graft survival of the patients in this study indicates that it is also an effective adjunctive therapy for promoting long-term graft survival. The problems encountered with early rerejection in high responder patients will promote an alteration of currently used protocols to accommodate these patients.

AB - OKT3 is a very effective drug when used for reversal of acute allograft rejection. The excellent long-term graft survival of the patients in this study indicates that it is also an effective adjunctive therapy for promoting long-term graft survival. The problems encountered with early rerejection in high responder patients will promote an alteration of currently used protocols to accommodate these patients.

UR - http://www.scopus.com/inward/record.url?scp=0021925539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021925539&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 39

EP - 41

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 1 I

ER -